Rafael Holdings Announces Last Patient Completed Final 96-Week Study Visit In Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C; Topline Results Expected In H2 Of Calendar 2026

Loading news article.

Rafael Holdings Announces Last Patient Completed Final 96-Week Study Visit In Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C; Topline Results Expected In H2 Of Calendar 2026 | WAPE

Rafael Holdings Announces Last Patient Completed Final 96-Week Study Visit In Pivotal Phase 3 TransportNPC Study Evaluating Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C; Topline Results Expected In H2 Of Calendar 2026

Article summary

Related companies

Comments —